- Home
- SLNO vs PRCT Comparison
SLNO vs PRCT Comparison
Compare SLNO & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- PRCT
- Stock Information
- Founded
- SLNO 1999
- PRCT 2009
- Country
- SLNO United States
- PRCT United States
- Employees
- SLNO N/A
- PRCT N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PRCT Medical Specialities
- Sector
- SLNO Health Care
- PRCT Health Care
- Exchange
- SLNO Nasdaq
- PRCT Nasdaq
- Market Cap
- SLNO 3.8B
- PRCT 3.2B
- IPO Year
- SLNO 2014
- PRCT 2021
- Fundamental
- Price
- SLNO $87.26
- PRCT $59.35
- Analyst Decision
- SLNO Strong Buy
- PRCT Buy
- Analyst Count
- SLNO 9
- PRCT 8
- Target Price
- SLNO $105.11
- PRCT $86.14
- AVG Volume (30 Days)
- SLNO 1.7M
- PRCT 740.5K
- Earning Date
- SLNO 08-06-2025
- PRCT 07-31-2025
- Dividend Yield
- SLNO N/A
- PRCT N/A
- EPS Growth
- SLNO N/A
- PRCT N/A
- EPS
- SLNO N/A
- PRCT N/A
- Revenue
- SLNO N/A
- PRCT $249,121,000.00
- Revenue This Year
- SLNO N/A
- PRCT $47.38
- Revenue Next Year
- SLNO N/A
- PRCT $31.71
- P/E Ratio
- SLNO N/A
- PRCT N/A
- Revenue Growth
- SLNO N/A
- PRCT 59.36
- 52 Week Low
- SLNO $41.50
- PRCT $47.04
- 52 Week High
- SLNO $90.32
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- SLNO 61.04
- PRCT 55.52
- Support Level
- SLNO $79.70
- PRCT $54.61
- Resistance Level
- SLNO $88.62
- PRCT $59.18
- Average True Range (ATR)
- SLNO 3.39
- PRCT 2.34
- MACD
- SLNO -0.01
- PRCT 0.14
- Stochastic Oscillator
- SLNO 73.63
- PRCT 100.00
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.